Out of $700bn in impact investing only 7% goes towards healthcare. But Johnson & Johnson is looking at ways to move the needle.
There is an estimated $700bn of impact investing going on, but only 7% of it is being directed at healthcare — so this is an area with a lot of room for improvement. This was the message from Sarah Hubar-Fisher, senior director of Global External Innovation at pharmaceutical firm Johnson & Johnson at the GCV Symposium.
Hubar-Fisher, however, has an idea for how to move…
